Detalhe da pesquisa
1.
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Ann Oncol
; 31(11): 1506-1517, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32891793
2.
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Ann Oncol
; 29(9): 1995-2002, 2018 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30084934
3.
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ann Oncol
; 27(9): 1794-9, 2016 09.
Artigo
Inglês
| MEDLINE | ID: mdl-27371698
4.
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Ann Oncol
; 25(1): 236-40, 2014 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-24356634
5.
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.
Br J Cancer
; 109(7): 1717-24, 2013 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-24022187
6.
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Ann Oncol
; 24(6): 1703-9, 2013 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-23385197
7.
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.
Ann Oncol
; 24(2): 537-542, 2013 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-23117071
8.
Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
Ann Oncol
; 23(12): 3180-3187, 2012 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-22858558
9.
Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
Ann Oncol
; 23(7): 1680-7, 2012 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-22357255
10.
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
Ann Oncol
; 23(3): 771-776, 2012 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-21642514
11.
Isolation and chromosomal localization of cDNAs encoding a novel human lymphocyte cell surface molecule, LAM-1. Homology with the mouse lymphocyte homing receptor and other human adhesion proteins.
J Exp Med
; 170(1): 123-33, 1989 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-2473156
12.
Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo.
J Exp Med
; 183(6): 2681-6, 1996 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-8676090
13.
A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Ann Oncol
; 21(10): 1990-1998, 2010 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-20507881
14.
KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Oncogene
; 26(44): 6386-95, 2007 Sep 27.
Artigo
Inglês
| MEDLINE | ID: mdl-17452978
15.
Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes.
J Clin Invest
; 86(4): 1261-9, 1990 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-2212010
16.
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
J Clin Oncol
; 23(24): 5484-92, 2005 Aug 20.
Artigo
Inglês
| MEDLINE | ID: mdl-16110008
17.
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Cancer Res
; 61(22): 8118-21, 2001 Nov 15.
Artigo
Inglês
| MEDLINE | ID: mdl-11719439
18.
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
Oncogene
; 20(36): 5054-8, 2001 Aug 16.
Artigo
Inglês
| MEDLINE | ID: mdl-11526490
19.
Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
J Clin Oncol
; 16(10): 3412-25, 1998 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-9779721
20.
A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo.
J Clin Oncol
; 7(10): 1545-53, 1989 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-2506316